Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs. Iodine I 131 Tositumomab in Relapsed Follicular NHL
NCT00078598Phase 3Unknown
- Sponsor
- Corixa Corporation
- Start
- Apr 2004
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iodine i 131 tositumomab in follicular lymphoma (FL) (2 arms), sponsored by Corixa Corporation. Primary endpoint: Progression-Free Survival at 5 years. Status: unknown.
02
Drugs
iodine i 131 tositumomab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00078598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078598.